Immunotherapy News and Research

Latest Immunotherapy News and Research

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

New biomarker can predict breast cancer recurrence

Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence.

17 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Simple tips for avoiding allergies and asthma during summer

Summertime means outdoor fun at weddings, graduations, festivals and picnics. But uninvited guests ranging from stinging insects to grass pollen can ruin the fun for the millions of Americans with allergies and asthma.

13 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Geron comments on recent European telomerase peptide cancer vaccine patents

Geron Corporation today commented on a ruling from the European Patent Office with regard to its European patent 084139, and the issuance of a second Geron patent covering telomerase peptides, EP1783139.

10 May 2011

KAEL-GemVax wins European telomerase patent challenge

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.

9 May 2011

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

OncoSec Medical Inc., a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

9 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

29 Apr 2011

Researchers develop new gene therapy technique for CGD treatment

Researchers have developed an effective technique that uses gene therapy on stem cells to correct chronic granulomatous disease in cell culture, which could eventually serve as a treatment for this rare, inherited immune disorder, according to a study published in Blood, the Journal of the American Society of Hematology.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

New biomarker can predict breast cancer recurrence

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Simple tips for avoiding allergies and asthma during summer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Inovio first quarter total revenue increases to $3.1 million for 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Geron comments on recent European telomerase peptide cancer vaccine patents

KAEL-GemVax wins European telomerase patent challenge

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

New nano-vault delivery system can fight cancer

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

Researchers develop new gene therapy technique for CGD treatment

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in